DIETETIC COMPOSITIONS CONTAINING DEACYLATED PHOSPHOLIPIDS

Abstract: Dietetic compositions useful as alimentary inte­ grators containing a mixture of soy natural deacylated phospholipid mixture (glycerophosphoryl-choline, -etha­ nolamine, -inositol, -serine) are described.

Description: The present invention concerns dietetic compositions containing soy natural deacylated phospholipids. The phospholipids are one of the hot topic in the biochemical research. Their presence in the cell membranes and in lipoproteins accounts for the crucial role they play in different biological functions such as oxidative phosphorylation, active transport, mitosis, etc.. The phospholipids have recently given rise to interest because of their prophylactic action against atherosclerotic pathology and of optimizing action with respect to neurotransmission. In particular, it has often been found the positive relationship between a suitable phospholipid intake and the onset of said actions and it has also been ascertained an often insufficient phospholipid intake. Significant problems connected with the intake of said substances are represented by the relative complexity of the deacylation processes necessary for their absorption, by the possible degradation of the saturated and unsaturated fatty acids bound thereto making their preservation difficult and, finally, by the cellular peroxidation processes connected with their presence and ascribable to the unsaturation of the acyl chains. It is known that the phospholipids after oral administration are cleaved in the gastro-enteric tract by specific phospholipases. Thus, phospholipase A₁ specifically hydrolizes the ester bond in position 1 whereas phospholipase A₂ hydrolizes that in position 2 producing a monoacylphospholipid named lysophosphatidyl-choline, -ethanolamine, -serine, -inositol. As reported in literature (H. Van den Bosch in "Phospholipids" , J.N. Hawthorne e G.B. Ansell, Eds., Elsevier Biomedical Press, Amsterdam, p. 313 "Phospholipases"; H. Van den Bosch, Ann. Rev. Biochem. , 43 , 243 (1974); A.J. Slotboom, H.M. Werheij, G.H. de Hass in "Phospholipases" J.N. Hawthorne, G.B. Ansell, Eds./, Elsevier Biomedical Press, p. 359, On the Mechanism of phospholipases A₂"; E.G. Lapetina, Ann. Rep. in Med. Chem., 19 , 213 (1984)), the phospholipids yielding glycerophosphobases by complete deacylation of 1-acyl-or 2-acyl-glycero phosphobases or of the deacylated phospholipids are widely spread (bowel, lung, spleen, liver, pancreas, muscles, kidneys, testis, brain, blood) (H. Van den Bosch, L.M.G. Van Golde, L.L.M. Van Deenen, Ann. Rev. Physiol., 66 , 13-145 (1972); E.A. Marples, R.H.S. Thompson, Biochem. J., 74 123-127 (1960)). The catabolic part of the diacylglycerophospholipids turnover is thought to occur in most cells by means of a stepwise deacylation catalyzed by phospholipases A₁, A₂ and ubiquitous lysophospholipases. It is also true that the "de novo" synthesis of phospholipids involves the acylation of the hydroxy group in position 1 with saturated fatty acids and of that in position 2 with unsaturated fatty acids. The biosynthesis of polyinsaturated phospholipids and particularly of phosphatidylinositol is significantly influenced by the alimentary intake of their precursors such as essential fatty acids, choline or, better, glycero-phosphorylcholine, inositol or, more completely, glycerophosphorylinositol. However the modern diet may be in different cases deficient as far as the intake of said substances is concerned and this is mostly due to processing operations to which different foods such as oils, flours, rice etc. are subjected. It has been calculated that the amount of bioavailable choline for a common "western-type" diet is about 300 mg/day whereas the recommended daily intake is 900 mg/day. There are therefore the conditions for considering that the onset of a state of latent deficiency of choline and inositol is a true risk and that said pre-deficiency affects the phospholipid biosynthesis negatively. The relative insufficiency of said substances in the diet may then cause the functional impairment of various enzymes (monoaminoxidases, ATPase, citidyl-phosphoryl-choline transferase, etc.) and also the structural impairment of plasmalemma and of the inner mithochondrial membrane. It has been found that the dietetic intake of a mixture of natural deacylated phospholipids (glycerophosphorylcholine, glycerophosphorylethanolamine, glycerophosphorylinositol, glycerophosphorylserine) gives the ideal solution to the problem of deficiency of the essential precursors for the phospholipid biosynthesis. Natural deacylated phospholipids, which are obtained from selected soy lecithins, allow in fact the preparation of alimentary integrators having, in comparison with similar known products comprising lecithins, i.e natural acylated phospholipids, the following advantages: ready bioavailability of deacylated phospholipids which may be immediately used by the organism; optimal organoleptic characteristics; hydrosolubility which can allow an easy formulation in different presentation forms suited also for the administration to elderly subjects and to infants; high stability and absence of degradation phenomena due to the peroxydation of unsaturated fatty acids. Said advantages are obtained using natural deacylated phospholipids, prepared by total saponification of the phosphatides mixtures contained in deoleated soy lecithin for alimentary use. The present composition (by weight) of the single components of the deacylated mixture is the following: glycerophosphorylcholine 30-50% glycerophosphorylethanolamine 20-40% glycerophosphorylinositol 10-20% glycerophosphorylserine 2-5% The compositions of the present invention can also contain other active ingredients or integrators having coadjuvant, complementary or anyway useful activities. Preferred embodiments of the invention include, for instance, samples of deacylated phospholipids added with nutritional elements giving even more peculiar and specific characteristics to the compositions. Examples of nutritional elements which can be used to this purpose are : alimentary fibres which can reduce an excessive food intake and normalize the intestinal functions, such as pectins, guar and konjac ( which can also decrease fat and carbohydrates absorptions and bile salt concentration in colon); zinc or zinc compounds, any deficiencies thereof involve negative physiological effects, particularly in case of chronic hepatoses or ageing phenomena; selenium or selenium compounds, which are useful due to the well known antiperoxide action thereof, which involves a protection of cellular and subcellular membranes against oxidative damages. A selenium deficiency is related to an increased risk of occurrence of tumoral forms, according to recent studies; vitamins, in particular vitamins A, E and C, which are known to have antioxidant properties and also to be cofactors or some important enzyme systems; essential fatty acids, particularly linolenic acid, which can favourably affect prostaglandin biosynthesis from arachidonic acid; amino acids, specifically branched amino acids (leucine, alanine and valine), whose administration is useful in case of hepatopathies. The dietetic compositions of the present invention are prepared according to conventional techniques and excipients. Examples of said compositions comprise syrups, beverages, jellies, candies, tablets The unitary dose ranges from 50 to 300 mg of deacylated natural phospholipid mixture, preferably about 100 mg. The following examples further illustrate the invention. EXAMPLE 1. SYRUP 100 ml of syrup (one dose = 5 ml) contain : EXAMPLE 2. MONODOSE SYRUP Each dose (10 ml) contains : EXAMPLE 3. FRUIT BEVERAGE 100 ml (one dose = 50 ml) contain : EXAMPLE 4. EXTEMPORARY BEVERAGE (10 g sachet) 10 g ( = one dose) contain : EXAMPLE 5. SOLUBLE GRANULATE 100 g ( one dose = 1 doser spoon) contain : EXAMPLE 6. FRUIT JELLIES 100 g ( one dose = 10 g) contain : EXAMPLE 7. TABLETS 100 g contain : EXAMPLE 8. CANDIES 100 g (one candy = 4 g) contain : EXAMPLE 9 DEACYLATED PHOSPHATIDES ADDED WITH FIBRES. CHEWABLE TABLETS. 100 g contain : EXAMPLE 10. DEACYLATED PHOSPHATIDES ADDED WITH VITAMINS AND MINERAL SALTS. CHEWABLE TABLETS. 100 g contain : EXAMPLE 11 DEACYLATED PHOSPHOLIPIDS ADDED WITH BRANCHED CHAIN AMINO ACIDS. CHEWABLE TABLETS. 100 g contain :

Claims: Claims for the following Contracting States : DE, GB, FR, IT, NL, SE, LI, CH, BE, AT, LU, DK, ES, GR Dietetic compositions containing deacylated natural phospholipids from selected soy lecithins. Dietetic compositions as claimed in claim 1, containing 50 to 300 mg per unitary dose of deacylated phospholipid mixture. Dietetic compositions as claimed in claims 1 or 2, containing 30 to 50% by weight glycerophosphorylcholine, 20 to 40% by weight glycerophosphorylethanolamine and 2 to 5% by weight glycerophosphorylserine. Dietetic compositions as claimed in any one of the preceding claims, containing other active ingredients or integrators having coadjuvant, complementary or useful activities. Dietetic compositions as claimed in claim 4, further containing at least one active ingredient or integrator selected from the group consisting of alimentary fibres, zinc, zinc compounds, selenium, selenium compounds, vitamins, essential fatty acids, amino acids. Dietetic compositions as claimed in any one of the preceding claims, in form of syrup, beverage, jelly, tablet, candy, granulate.

Inventors: PALAZZI, CAMILLO MARIA FRANCESCO GIULIO, PROCIDA, CARLA, SCOLASTICO, SILVIA
Applicants: DEPHA TEAM S.R.L.
Application year: 1990
Main classification: A23L1
IPC codes: A23L1, A23J7, A21D13, A21D2